Login to Your Account



Coley Stock Plunges As Pfizer Abandons NSCLC Program

By Glen Harris


Thursday, June 21, 2007
Shares of Coley Pharmaceutical Group Inc. sank nearly 60 percent Wednesday on news that partner Pfizer Inc. has walked away from the investigation lung cancer drug PF-3512676, shelving two Phase III and two Phase II trials. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription